product pipeline

Discovery Preclinical Phase 1 Phase 2 Phase 3 Market
ONCOLOGY  
Acromegaly
Octreotide (C2L) [1]		 completed completed completed completed completed
Prostate Cancer
Goserelin		 completed completed completed in progress
Prostate Cancer
PCK3145		 completed completed completed
Cancer
NGR-Delivery Technology		 completed completed
VIROLOGY  
HIV/AIDS  
Protease Inhibitors [2] completed completed completed
Integrase Inhibitors completed
Entry Inhibitors completed
HCV  
Polymerase Inhibitors completed
Entry Inhibitors completed
Influenza A  
M2 Proton Channel Inhibitors completed

(1) Licensed to TEVA (France, Germany, Benelux, Spain, Scandinavia), Archimedes Pharma (U.K.), Gerolymatos (Greece, Turkey, other countries), Kwidza Pharma (Austria), Omega (Canada, Egypt), Pharmis (Portugal, Brazil), Shin Poong (Korea), and others

(2) Licensed to Merck & Co. worldwide (development on hold)